Clinical Trials Directory

Trials / Unknown

UnknownNCT02438748

Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression

The Role of Biological Stress Markers in Predicting Treatment Response to Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder

Status
Unknown
Phase
Study type
Observational
Enrollment
310 (estimated)
Sponsor
University of Manitoba · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

The main objective of this study is to determine whether biological stress markers (Oxidized Phosphatidylcholines and Oxylipins) in the blood can be used to predict the efficacy of rTMS in the treatment of major depressive disorder (MDD). It is our goal to identify biomarkers that may be used to determine which patients will benefit from rTMS treatment. A second objective of this study is to measure any changes in stress markers that occur across the course of rTMS therapy.

Detailed description

250 patients who have been prescribed repetitive transcranial magnetic stimulation (rTMS) therapy for the treatment of major depressive disorder will be recruited for this study. Prior to undergoing rTMS, patients will give a small blood sample. An additional blood sample will be given upon completion of rTMS treatment. 60 healthy control individuals will also be recruited to provide a one-time blood sample for comparison. Control individuals will not receive rTMS treatment. Blood samples will be analysed for levels of Oxidized Phosphatidylcholines and Oxylipins. The investigators wish to determine whether there is a difference in the pre-treatment levels of stress markers between individuals who ultimately respond to rTMS and those who do not. Additionally, the investigators wish to determine whether there is a change in stress markers as a result of rTMS treatment.

Conditions

Interventions

TypeNameDescription
DEVICERepetitive Transcranial Magnetic StimulationA non-invasive method of brain stimulation.

Timeline

Start date
2015-05-01
Primary completion
2022-01-01
Completion
2022-05-01
First posted
2015-05-08
Last updated
2020-11-04

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02438748. Inclusion in this directory is not an endorsement.